Join NBTS’s campaign to raise awareness about the importance of biomarker testing and clinical trials for patients with brain tumors.
READ MOREPublished on November 15, 2022 in ResearchEOY, Press Release
National Brain Tumor Society (NBTS), the nation’s largest nonprofit dedicated to defeating brain tumors and improving the quality of brain tumor patients’ lives, and IQVIA, a leading global provider of advanced analytics, technology solutions, and clinical research services, have announced a collaboration through IQVIA Biotech to support the development of DNA Damage Repair inhibitors for malignant brain tumors.
IQVIA, long involved with the development of early phase and experimental treatments, will be supporting NBTS’s new research initiative, the DNA Damage Response Consortium (DDR-C). The DDR-C brings together a diverse team of renowned adult and pediatric researchers to rapidly advance a new class of promising potential treatments that can target a brain tumor’s DNA damage response network.
The DDR-C seeks to fuel rapid evaluation of novel and repurposed DNA Damage Response drugs in pre-clinical and early phase clinical settings with the goal of qualifying and advancing the best drugs for clinical trials.
“IQVIA has long been committed to making a difference for patients through collaborations with those pursuing innovative research and development of cutting-edge therapies,” said Dr. James Kyle Bryan, Chief Medical Officer, IQVIA Biotech. “This partnership extends that mindset of commitment by helping to advance these therapeutics for this vulnerable patient population.”
This partnership will help power DDR-C translational science, clinical candidate identification/validation, other preclinical studies, and early phase clinical trial planning. By combining the NBTS’s DDR-C and patient advocacy program with IQVIA’s industry-leading expertise in patient and research data and clinical trials, the partnership aims to pave the way for more patient-centered research opportunities.
“The DDR-C creates an opportunity for biotechnology and biopharmaceutical companies to accelerate the preclinical evaluation of their most promising DDR related candidates,” said David Arons, Chief Executive Officer of NBTS. “Partnering with an organization like IQVIA, which has extensive experience in health care and clinical trial operations, provides an exciting opportunity to support this innovative consortium and move potentially transformative treatments emerging from these world class laboratories into innovative clinical studies.”
About the National Brain Tumor Society
Building on over 30 years of experience, the National Brain Tumor Society (NBTS) unrelentingly invests in, mobilizes, and unites the brain tumor community to discover a cure, deliver effective treatments, and advocate for patients and caregivers. Our focus on defeating brain tumors and improving the quality of patients’ lives is powered by our partnerships across the science, health care, policy, and business sectors. We fund treatments-focused research and convene those most critical to curing brain tumors— once and for all.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 85,000 employees, IQVIA conducts operations in more than 100 countries.
TAGGED WITH: brain cancer, brain tumor, Treatment, Research, Clinical trials